Sidebar

Velo3D’s Common Stock to Begin Trading on the New York Stock Exchange Under the Ticker “VLD” on September 30, 2021

Transaction Delivers $274 Million to Support the Adoption of Velo3D’s End-to-End Manufacturing Solutions

Velo3D to Celebrate Milestone by Ringing the New York Stock Exchange Closing Bell on October 7, 2021

Led by Volta Energy Technologies, the new investment enables 6K to further develop strategic material production processes focused on sustainability and lower costs while setting the stage for supply chain independence and domestic production for battery materials

BCN3D obtains a key technology as well as expertise for the development of its cloud solutions, remaining dedicated to improving user experience and offering features never before seen on the market

CTO and Co-founder of AstroPrint Daniel Arroyo has been appointed Chief Software Officer of BCN3D. Arroyo will lead the joined forces of the BCN3D and AstroPrint software teams for this strategic move for BCN3D’s alignment of software to hardware

Brinter was thrilled to meet people in person and create new contacts at the Biocity Symposium with the title CANCER – BREAKING BAD in Turku last week. Finally, a partly physical and partly virtual scientific meeting could be arranged despite the COVID-19 situation and allowed us to demonstrate Brinter® 3D bioprinting platform in action! As you are aware, cancer research is one of Brinter’s core application areas.

The first in-person trade fairs have already taken place. Messe Frankfurt is ready to resume in-person events with its proven safety and hygiene concept and requirement that everyone be vaccinated, recovered or tested. The first events have already been held successfully, and the next in-person events will be opening their doors in Frankfurt in September.

Evonik has raised its outlook for 2021 after posting strong earnings in the first half. Demand for Evonik products increased significantly worldwide with sales prices also rising.

Sales rise 29 percent in second quarter, adjusted EBITDA gains 42 percent
All three growth divisions deliver results above pre-crisis levels of 2019
Outlook 2021: Adjusted EBITDA now expected to be €2.3 billion to €2.4 billion

Evonik is extending its corporate venture capital activities in China with investments into GRC SinoGreen Fund V and Richland VC Fund III.

The investment underlines the importance of China as rapidly growing venture capital region
The two leading funds will strengthen Evonik’s access to China’s fast-growing innovation ecosystem

Meet Our Sponsors

Latest Sponsor News

Articles Most Read

Latest News

Statistics

Articles View Hits
2700488

Who's Online

We have 78 guests and no members online